Travere Therapeutics
Manufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
3611 Valley Centre Dr Ste 300, San Diego...Phone Number
(888) 969-7879Website
www.travere.comRevenue
$536.2 MillionStock Symbol
TVTXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Travere Therapeutics
Travere Therapeutics Inc. is a biopharmaceutical company. It develops drugs for therapies for people living with liver, rare kidney, and metabolic diseases. The company was founded as Retrophin, Inc. in 2011 is based in San Diego, California.Explore more
Travere Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Travere Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Travere Therapeutics has new funding data
Check if Travere Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Travere Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Travere Therapeutics is spiking on competitors!
Product Launch: Get notified when Travere Therapeutics launches new products
Earning: See what the market has to say on Travere Therapeutics recently announced quarterly report
Travere Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Travere Therapeutics had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Travere Therapeutics
Compare insights from companies similar to Travere Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Travere Therapeutics
$536.2M
201-500
Public
$175.2M
2011
ER
Elizabeth ReedSenior Vice President, General Counsel & Secretary
$191.6M
201-500
Private
$300M
2017
PP
Pamela Papino-WoodGlobal Vice President, Medical Operations & Excellence
Company Profile Activity
Activity Insights
Travere Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Travere Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Travere Therapeutics.
Travere Therapeutics financials insights
Gather financial insights about Travere Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Stock Offering
$175.2M
Travere Therapeutics Tech Stack
A closer look at the technologies used by Travere Therapeutics
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Travere Therapeutics News & Media
Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?
Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on Biotech Distilled’s Substack. In this article, we will summarize the bulls’ thesis on TVTX. Travere Therapeutics, Inc.’s share was trading at $47.08 as of June 8th. TVTX’s forward P/E was 63.29 according to Yahoo Finance. Travere Therapeutics, Inc., a […]Travere Therapeutics, Inc. (TVTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Travere Therapeutics, Inc. (TVTX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 11:20 AM EDTCompany ParticipantsEric Dube -...Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion
HONG KONG, Jun 4, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor in all markets outside China and certain countries in East and Southeast Asia. Under the terms of the agreement, ETravere beefs up rare kidney disease portfolio with up to $1.1B China deal - BioSpace
Travere Therapeutics will gain an exclusive license to the oral BTK inhibitor civorebrutinib, which analysts at Guggenheim Securities said could be “complementary” to the biotech’s IgA nephropathy drug Filspari.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Travere Therapeutics
Sign Up For FreeTo access detailed company insights
Travere Therapeutics Inc. is a biopharmaceutical company. It develops drugs for therapies for people living with liver, rare kidney, and metabolic diseases. The company was founded as Retrophin, Inc. in 2011 is based in San Diego, California.... Read More
